|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-9-28
|
|
pubmed:abstractText |
Conditionally-replicating adenovirus (CRAd) therapy is currently being tested against pancreatic cancer and has shown some promise. To improve the efficacy, a novel virus CRAd-Cans was designed by deletion of E1B-55kDa gene for selective replication in tumor cells, as well as carrying a new angiogenesis inhibitor gene, canstatin. CRAd-Cans mediated higher expression of canstatin in BxPC-3 pancreatic cancer cell line compared to the replication-deficient adenovirus Ad5-Cans. The modified CRAd-Cans manifested the same selective replication and cytocidal effects in pancreatic cancer cells as ONYX-015 in vitro, yet showed greater reduction of tumor growth in nude mice with markedly prolonged survival rate in vivo (P<0.05), compared to that of either ONYX-015 or Ad5-Cans. Pathological examination revealed viral replication, decreased microvessel density and increased cancer cell apoptosis in CRAd-Cans-treated xenografts. The results suggest that the novel oncolytic virus CRAd-Cans, showing synergistic effects of oncolytic therapy and anti-angiogenesis therapy, is a new promising therapeutics for pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1872-7980
|
|
pubmed:author |
pubmed-author:CoxS GSG,
pubmed-author:GongYang-FangYF,
pubmed-author:HeXiao-PingXP,
pubmed-author:JinJingJ,
pubmed-author:LiHong-DaHD,
pubmed-author:LiZhao-ShenZS,
pubmed-author:LiaoZhuanZ,
pubmed-author:ManXiao-HuaXH,
pubmed-author:PanXueX,
pubmed-author:SuChang-QingCQ,
pubmed-author:TuZhen-XingZX,
pubmed-author:WangXing-HuaXH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
18
|
|
pubmed:volume |
285
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
89-98
|
|
pubmed:dateRevised |
2010-5-20
|
|
pubmed:meshHeading |
pubmed-meshheading:19481338-Adenoviridae,
pubmed-meshheading:19481338-Adenovirus E1B Proteins,
pubmed-meshheading:19481338-Animals,
pubmed-meshheading:19481338-Cell Line, Tumor,
pubmed-meshheading:19481338-Cell Proliferation,
pubmed-meshheading:19481338-Cell Survival,
pubmed-meshheading:19481338-Collagen Type IV,
pubmed-meshheading:19481338-Gene Deletion,
pubmed-meshheading:19481338-Humans,
pubmed-meshheading:19481338-Male,
pubmed-meshheading:19481338-Mice,
pubmed-meshheading:19481338-Mice, Inbred BALB C,
pubmed-meshheading:19481338-Mice, Nude,
pubmed-meshheading:19481338-Oncolytic Virotherapy,
pubmed-meshheading:19481338-Oncolytic Viruses,
pubmed-meshheading:19481338-Pancreatic Neoplasms,
pubmed-meshheading:19481338-Peptide Fragments,
pubmed-meshheading:19481338-Time Factors,
pubmed-meshheading:19481338-Virus Replication,
pubmed-meshheading:19481338-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
|
|
pubmed:affiliation |
Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
